Table 2.
Identifies the Manifestation of the Adverse Events Observed During the Follow-Up Periods
| Type of Adverse Events | Frequency of A.E.’s in MSC Treatment | Frequency of A.E.’s in Control |
|---|---|---|
| Blood & Lymphatic system disorder | 1 | 1 |
| Endocrine disorders | 2 | 0 |
| Eye disorder | 1 | 0 |
| Gastrointestinal disorders | 4 | 5 |
| General disorder and site of Injection Administration | 84 | 27 |
| Infection & Infestation | 14 | 7 |
| Injury, Procedural & Poisoning | 11 | 3 |
| Investigation | 4 | 3 |
| Metabolism & Nutrition disorders | 4 | 4 |
| Musculoskeletal & Connective tissue | 72 | 20 |
| Nervous system disorders | 2 | 1 |
| Urinary and renal disorders | 2 | 0 |
| Reproductive system disorders | 2 | 0 |
| Respiratory, Thoracic & Mediastinal disorders | 1 | 1 |
| Skin & Subcutaneous tissue disorder | 1 | 1 |
| Surgical & Medical procedure complications | 3 | 0 |
| Vascular disorders | 3 | 2 |
| Immune System | 2 | 1 |
| Total # of AEs | 213 | 76 |